For years, “yo-yo dieting” has carried a warning: Lose weight, regain it and you may end up worse off than before. The fear is familiar. Repeated weight loss and regain is often said to slow metabolism, increase fat gain, reduce muscle mass and make future weight loss harder.
A new expert analysis published in The Lancet Diabetes & Endocrinology challenges that assumption. The article, written by researchers from the University of Copenhagen and the German Center for Diabetes Research, argues that there is not strong causal evidence that weight cycling itself causes long-term metabolic harm in people with obesity.
The article is not a new clinical trial. It is an invited “Personal View,” meaning the authors reviewed and interpreted existing evidence from observational studies, randomized clinical trials and animal research. Their main argument is that the harms often blamed on weight cycling may be better explained by other factors, including aging, preexisting health conditions and the amount of time a person lives with higher body weight.
“Many people struggling with weight are discouraged from trying to lose weight because they fear ‘yo-yo dieting’ will lead to muscle loss and somehow damage their metabolism,” said Prof. Faidon Magkos of the University of Copenhagen. “Our review indicates that these fears are largely unsupported. In most cases, the benefits of trying to lose weight clearly outweigh the theoretical risks of weight cycling.”
That does not mean weight regain is harmless in every way. When people lose weight, they may see improvements in blood sugar, blood pressure, cholesterol, liver fat, mobility, sleep or quality of life. Regaining weight can reduce or erase many of those benefits.
But the authors argue that losing those benefits is not the same as proving that weight cycling causes additional damage.
“Regaining weight brings people back toward baseline risk — not beyond it,” Magkos said. “There’s a crucial difference between losing benefits and causing harm.”
The distinction matters because many people with obesity experience repeated weight-loss attempts over time. Long-term weight maintenance is difficult, and weight regain is common after lifestyle programs, obesity medications and other treatments. With the rise of GLP-1 and dual incretin medications, the question has become even more relevant because stopping treatment can lead to substantial regain for some patients.
The authors say that pattern should not automatically be interpreted as evidence of harm. Instead, periods of weight reduction may still provide meaningful windows of improved metabolic health and quality of life, even if weight loss is not fully maintained.
The analysis also pushes back on two common fears: that repeated dieting permanently suppresses metabolism and that weight cycling causes disproportionate muscle loss. According to the authors, studies that objectively track body composition do not consistently show that weight cycling causes people to return with less lean mass or a worse body composition than before. In many cases, people who regain weight return closer to their starting point.
That is still not the same as saying all weight-loss attempts are healthy. Highly restrictive diets, poor nutrition, disordered eating patterns, weight stigma and repeated cycles of shame can be harmful, regardless of what happens metabolically. A safer interpretation is that weight cycling itself may not be the metabolic disaster it is often portrayed to be.
The article also does not remove the need for better long-term support. If weight regain reverses health improvements, then helping people maintain healthy behaviors, preserve muscle, eat enough protein, stay active and receive appropriate medical care still matters.
The findings may be reassuring for people who have lost weight, regained it and felt as though they damaged their bodies. The evidence reviewed by the authors suggests that the story is more complicated and less discouraging than the usual “yo-yo dieting ruins your metabolism” message.
Magkos received consultancy fees from AstraZeneca and research support from the Novo Nordisk Foundation and Arla Food for Health. Another author, Norbert Stefan, received fees for consultancy and scientific talks from AstraZeneca, Boehringer Ingelheim, Lilly, Novo Nordisk, Pfizer and Sanofi. He also received research support from AstraZeneca, Boehringer Ingelheim and Sanofi.
The work was aided in part by funding from the German Federal Ministry of Education and Research to the German Center for Diabetes Research and the European Innovative Medicines Initiative SOPHIA.